Integrative Analysis of FOXP1 Function Reveals a Tumor-suppressive Effect in Prostate Cancer

Overview

Journal Mol Endocrinol

Specialties Endocrinology
Molecular Biology

Date 2014 Oct 21

PMID 25329375

Citations 36

Authors

Ken-Ichi Takayama

Takashi Suzuki

Shuichi Tsutsumi

Tetsuya Fujimura

Satoru Takahashi

Yukio Homma

Tomohiko Urano

Hiroyuki Aburatani

Satoshi Inoue

Affiliations

Soon will be listed here.

Abstract

The transcriptional network of the androgen receptor (AR), a key molecule of prostate cancer, is frequently modulated by interactions with other transcriptional factors such as forkhead box protein A1 (FOXA1). However, global regulatory mechanisms of AR signaling mediated by such factors have not been well investigated. Here we conducted a chromatin immunoprecipitation sequence analysis, which revealed that another FOX family, FOXP1, is specifically regulated by both AR and FOXA1. We also found that FOXP1 acts as a tumor suppressor in prostate cancer through inhibiting cell proliferation and migration. We generated an extensive global map of FOXP1 binding sites and found that FOXP1 is directly involved in AR-mediated transcription. We demonstrated that FOXP1 has a repressive effect on AR-induced transcriptional activity or histone modification in enhancer regions. Moreover, by a global analysis of androgen-mediated transcriptional networks, we observed enrichment of FOXP1 binding genes in the gene cluster negatively regulated by FOXP1. Evaluation of FOXP1 expression in clinical samples indicated that the decreased expression of FOXP1 is another prognostic factor of prostate cancer. Taken together, our results suggest a novel mechanism in which AR-induced FOXP1 functions as a direct modulator of the AR and FOXA1 centric global transcriptional network.

Citing Articles

FOXP1 phosphorylation antagonizes its O-GlcNAcylation in regulating ATR activation in response to replication stress.

Zhu X, Gao C, Peng B, Xue J, Xia D, Yang L EMBO J. 2024; 44(2):457-483.

PMID: 39623140 PMC: 11729909. DOI: 10.1038/s44318-024-00323-x.

High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.

Zhang N, Harbers L, Simonetti M, Diekmann C, Verron Q, Berrino E Nat Commun. 2024; 15(1):3475.

PMID: 38658552 PMC: 11043350. DOI: 10.1038/s41467-024-47664-z.

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.

Rao S, Verrill C, Cerundolo L, Alham N, Kaya Z, OHanlon M Genome Med. 2024; 16(1):35.

PMID: 38374116 PMC: 10877771. DOI: 10.1186/s13073-024-01302-x.

Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma.

Tang C, Zhuang H, Tong H, Yu X, Chen J, Wang Q BMC Cancer. 2024; 24(1):137.

PMID: 38279090 PMC: 10811915. DOI: 10.1186/s12885-024-11882-x.

Immunohistochemistry technique for effect of gold nanoparticles, laser, and photodynamic therapy on FoxP1 level in infected mice with mammary adenocarcinoma.

Hussein S, Al-Yasiri A, Hassan H, Kashman B, Azeez R Lasers Med Sci. 2023; 38(1):106.

PMID: 37074483 DOI: 10.1007/s10103-023-03765-7.

References

Guseva N, Rokhlin O, Bair T, Glover R, Cohen M . Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor. Oncotarget. 2012; 3(2):183-94. PMC: 3326648. DOI: 10.18632/oncotarget.449. View

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M . Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2012; 328(2):198-206. DOI: 10.1016/j.canlet.2012.09.017. View

Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A . Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011; 30(19):3962-76. PMC: 3209787. DOI: 10.1038/emboj.2011.328. View

Takayama K, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T . TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol Endocrinol. 2012; 26(5):748-61. PMC: 5417095. DOI: 10.1210/me.2011-1242. View

Hermans K, van der Korput H, van Marion R, van de Wijngaart D, Ziel-van der Made A, Dits N . Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 2008; 68(18):7541-9. DOI: 10.1158/0008-5472.CAN-07-5930. View

Wang B, Lin D, Li C, Tucker P . Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. J Biol Chem. 2003; 278(27):24259-68. DOI: 10.1074/jbc.M207174200. View

Takayama K, Inoue S . Transcriptional network of androgen receptor in prostate cancer progression. Int J Urol. 2013; 20(8):756-68. DOI: 10.1111/iju.12146. View

Chng K, Chang C, Tan S, Yang C, Hong S, Sng N . A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J. 2012; 31(12):2810-23. PMC: 3380210. DOI: 10.1038/emboj.2012.112. View

10.

Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y . Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011; 474(7351):390-4. PMC: 3117022. DOI: 10.1038/nature10006. View

11.

Takayama K, Horie-Inoue K, Katayama S, Suzuki T, Tsutsumi S, Ikeda K . Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 2013; 32(12):1665-80. PMC: 3680743. DOI: 10.1038/emboj.2013.99. View

12.

Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T . FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol. 2011; 180(2):848-61. DOI: 10.1016/j.ajpath.2011.10.021. View

13.

Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K . Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene. 2010; 30(5):619-30. DOI: 10.1038/onc.2010.436. View

14.

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

15.

Murata T, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D . 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. Clin Cancer Res. 2012; 18(20):5617-27. DOI: 10.1158/1078-0432.CCR-12-0281. View

16.

Cai C, He H, Chen S, Coleman I, Wang H, Fang Z . Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011; 20(4):457-71. PMC: 3225024. DOI: 10.1016/j.ccr.2011.09.001. View

17.

Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, Dhanasekaran S . Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2006; 39(1):41-51. DOI: 10.1038/ng1935. View

18.

Li S, Weidenfeld J, Morrisey E . Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. Mol Cell Biol. 2004; 24(2):809-22. PMC: 343786. DOI: 10.1128/MCB.24.2.809-822.2004. View

19.

Banham A, Beasley N, Campo E, Fernandez P, Fidler C, Gatter K . The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001; 61(24):8820-9. View

20.

Lupien M, Eeckhoute J, Meyer C, Wang Q, Zhang Y, Li W . FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008; 132(6):958-70. PMC: 2323438. DOI: 10.1016/j.cell.2008.01.018. View